Altered plasma antigen levels of tissue factor pathway inhibitor during open-heart surgery

Surgery Today

Volumn 30, Issue 2, 2000, Pages 122-126

  Sun, Ling Bo ^a   Utoh, Junichi ^a   Kunitomo, Ryuji ^a   Tsurusaki, Shigeyuki ^a   Tagami, Hirofumi ^a   Hirata, Tomomi ^a   Moriyama, Shuji ^a   Okamoto, Ken ^a   Kitamura, Nobuo ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiopulmonary bypass; Coagulation; Open heart surgery; Tissue factor pathway inhibitor

Indexed keywords

ANTIGEN; CHROMOGENIC SUBSTRATE; HEPARIN; PROTAMINE; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART MUSCLE ISCHEMIA; HEART VALVE REPLACEMENT; HUMAN; MALE; OPEN HEART SURGERY; OPERATION DURATION; REPERFUSION INJURY;

EID: 0034006462     PISSN: 09411291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005950050027     Document Type: Article

References (29)

1. Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheikh S, Hunt B, Smith KJ (1993) Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 82:3350-3357
2. Kappelmayer J, Bernabei A, Edmunds LH Jr, Edgington TS, Colman RW (1993) Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res 72:1075-1081
3. Broze GJ Jr (1995) Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 46:103-112
4. Lindahl AK (1997) Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle. Cardiovasc Res 33:286-291
5. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr (1989) Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264: 18832-18837
6. Kokawa T, Abumiya T, Kimura T, Harada-Shiba M, Koh H, Tsushima M, Yamamoto A, Kato H (1995) Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vasc Biol 15:504-510
7. Sandset PM, Abildgaard U, Larsen ML (1988) Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50:803-813
8. Hubbard AR, Weller LJ, Gray E (1994) Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coag Fibrinol 5:819-823
9. Sandset PM, Roise O, Aasen AO, Abildgaard U (1989) Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases. Haemostasis 19:189-195
10. Lindhahl AK, Jacobsen PB, Sandset PM, Abildgaard U (1991) Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coag Fibrinol 2:713-721
11. Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, Mori Y, Shiku H (1997) Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 55:169-174
12. Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiku H, Tanigawa M, Nishikawa H, Yamada N, Isaka N, Nakano T, Kumeda K, Kato H (1997) Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol 55:183-187
13. Cardigan RA, Hamilton-Davies C, McDonald S, Purdy G, Mackie IJ, Webb AR, Machin SJ (1996) Haemostatic changes in the pulmonary blood during cardiopulmonary bypass. Blood Coag Fibrinol 7:567-577
14. Jeske W, Hoppensteadt D, Fareed J, Bermes E (1995) Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations. Blood Coag Fibrinol 6(Suppl 1):S73-S80
15. Kamei S, Kamikubo Y, Hamuro T, Fujumoto H, Ishihara M, Yonemura H, Miyamoto S, Funatsu A, Enjyoji K, Abumiya T, Miyata T, Kato H (1994) Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): comparison with human TFPI. J Biochem 115:708-714
16. Abumiya T, Enjyoji K, Kokawa T, Kamikubo Y, Kato H (1995) An anti-tissue factor pathway inhibitor (TFPI) monoclonal anti-body recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem 118:178-182
17. Teien AN, Lie M (1977) Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 10:399-410
18. Kokawa T, Enjyoji K, Kumeda K, Kamikubo Y, Harada SM, Koh H, Tsushima M, Yamamoto A, Kato H (1996) Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol 16:802-808
19. Leurs PB, van Oerle R, Hamulyak K, Wolffenbuttel BH (1995) Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes 44:80-84
20. Hansen JB, Sandset PM, Huseby KR, Huseby NE, Nordoy A (1996) Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 76:703-709
21. Chung JH, Gikakis N, Rao AK, Drake TA, Colman RW, Edmunds LH Jr (1996) Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 93:2014-2018
22. Barstad RM, Ovrum E, Ringdal MA, Oystese R, Hamers MJ, Veiby OP, Rolfsen T, Stephens RW, Sakariassen KS (1996) Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit. Br J Haematol 94:517-525
23. Sendset PM, Warn-Cramer BJ, Rao LV, Maki SL, Rapaport SI (1991) Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 88:708-712
24. Sendset PM, Warn-Cramer BJ, Maki SL, Rapaport SI (1991) Immunodepletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Schwartzman reaction. Blood 78:1496-1502
25. Nishiyama K, Ogawa H, Yasue H, Soejima H, Misumi K, Kugiyama K, Tsuji I, Kumeda K (1998) Heparin-releasable endothelial cell-associated tissue factor pathway inhibitor (TFPI) is increased in the coronary circulation after coronary spasm in patients with coronary spastic angina. Thromb Res 89:137-146
26. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG (1998) Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 79:495-499
27. Kraemer BA, Yu CD, Ornberg RL, Wun T-C, Koudsi BM (1995) The effects of tissue factor pathway inhibitor (TFPI) on tissue ischemia and reperfusion in a rabbit ear model. Surg Forum 46:738-740
28. Koudsi B, Chatman DM, Ballinger BA, Ferguson EW, Kraemer BA, Miller GA, Wun T-C, Farr G, Money SR (1996) Tissue factor pathway inhibitor protects the ischemic spinal cord. J Surg Res 63:174-178
29. Boyle EM Jr, Verrier ED, Spiess BD (1996) Endothelial cell injury in cardiovascular surgery: the procoagulant response. Ann Thorac Surg 62:1549-1557